These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 19111451)

  • 1. Metabolic syndrome and prostate cancer: a review.
    Nobes JP; Langley SE; Laing RW
    Clin Oncol (R Coll Radiol); 2009 Apr; 21(3):183-91. PubMed ID: 19111451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of metabolic syndrome, cardiovascular disease, and diabetes in androgen deprivation therapy.
    Leahy Y
    Clin J Oncol Nurs; 2008 Oct; 12(5):771-6. PubMed ID: 18842533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologic effects of testosterone deprivation.
    Sprenkle PC; Fisch H
    Curr Opin Urol; 2007 Nov; 17(6):424-30. PubMed ID: 17921778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen deprivation therapy for prostate cancer: current status and future prospects.
    Miyamoto H; Messing EM; Chang C
    Prostate; 2004 Dec; 61(4):332-53. PubMed ID: 15389811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is hormone ablation still the right choice for advanced prostate cancer?
    Fitzpatrick JM
    BJU Int; 2007 Jul; 100 Suppl 2():36-9. PubMed ID: 17594357
    [No Abstract]   [Full Text] [Related]  

  • 7. Emerging cardiometabolic complications of androgen deprivation therapy.
    Choong K; Basaria S
    Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hormone therapy for prostate cancer].
    Théodore C
    Bull Cancer; 2004 Jan; 91(1):69-74. PubMed ID: 14975807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen deprivation therapy for prostate cancer.
    Bahnson R
    J Urol; 2007 Oct; 178(4 Pt 1):1148. PubMed ID: 17698142
    [No Abstract]   [Full Text] [Related]  

  • 10. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?
    Higano CS
    Nat Clin Pract Urol; 2008 Jan; 5(1):24-34. PubMed ID: 18185511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of advanced prostate cancer: can we improve on androgen deprivation therapy?
    Anderson J; Abrahamsson PA; Crawford D; Miller K; Tombal B
    BJU Int; 2008 Jun; 101(12):1497-501. PubMed ID: 18336613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A critical review of the concept of total androgen ablation in the treatment of prostate cancer.
    Schulze H; Isaacs JT; Coffey DS
    Prog Clin Biol Res; 1987; 243A():1-19. PubMed ID: 3309968
    [No Abstract]   [Full Text] [Related]  

  • 13. Reimbursement policy and androgen-deprivation therapy for prostate cancer.
    Shahinian VB; Kuo YF; Gilbert SM
    N Engl J Med; 2010 Nov; 363(19):1822-32. PubMed ID: 21047226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation therapy for prostate cancer: friend or foe to the cardiovascular system?
    Zhang K; Zhang L; Hao Z; Liang C
    World J Urol; 2016 Jun; 34(6):879-81. PubMed ID: 26424563
    [No Abstract]   [Full Text] [Related]  

  • 15. Does the benefit justify the risk?
    Albertsen PC
    J Natl Cancer Inst; 2010 Jan; 102(1):4-5. PubMed ID: 19996059
    [No Abstract]   [Full Text] [Related]  

  • 16. What to do if prostate cancer returns.
    Johns Hopkins Med Lett Health After 50; 2001 Dec; 13(10):6-7. PubMed ID: 11727445
    [No Abstract]   [Full Text] [Related]  

  • 17. Treating prostate cancer. Part V: androgen deprivation and chemotherapy.
    Harv Mens Health Watch; 1999 Dec; 4(5):5-8. PubMed ID: 10564905
    [No Abstract]   [Full Text] [Related]  

  • 18. Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy.
    Bao BY; Pao JB; Huang CN; Pu YS; Chang TY; Lan YH; Lu TL; Lee HZ; Juang SH; Chen LM; Hsieh CJ; Huang SP
    Clin Cancer Res; 2011 Feb; 17(4):928-36. PubMed ID: 21149617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial comment.
    Shepard DR
    Urology; 2010 May; 75(5):1137. PubMed ID: 20451735
    [No Abstract]   [Full Text] [Related]  

  • 20. Metabolic syndrome and androgen deprivation therapy in metabolic complications of prostate cancer patients.
    Yuan JQ; Xu T; Zhang XW; Yu LP; Li Q; Liu SJ; Huang XB; Wang XF
    Chin Med J (Engl); 2012 Oct; 125(20):3725-9. PubMed ID: 23075732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.